-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This collaborative study of US researchers from the Central Brain Tumor Registry, by Kimberly D.
Although the incidence of malignant tumors is declining overall, the survival rate is still very low-only 36% of patients survive for more than 5 years after diagnosis, compared with 26% in the mid-1970s
The incidence of non-malignant tumors (mainly affecting women and blacks) is slowly increasing, which may be due to improved case detection and increased awareness
The report also found persistent differences between children
"Although molecular research on how brain cancers are distinguished from each other is advancing rapidly, we still know very little about the causes of these tumors in the first place
The report also pointed out the difference in incidence of different genders:
The incidence of malignant brain tumors in men (8.
On the contrary, the incidence of non-malignant tumors in women (20.
For malignant tumors, the gender difference is the largest among people aged 45 and over, and the incidence of women is 30% lower than that of men
For non-malignant tumors, the gender difference peaks at the age of 25-29, and the incidence of women is twice that of men (10.
Journal Reference :
Miller KD, Ostrom QT, Kruchko C, Patil N, Teehan T, Cioffi, G, Fuchs HE, Waite K, Jemal A, Siegel RL, Barnholtz-Sloan the JS.
